Security key
64136E102
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP)
CUSIP: 64136E102
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, $0.00001 par value per share
- Shares outstanding
- 5,420,049
- Total 13F shares
- 163,114
- Share change
- +83,395
- Total reported value
- $935,356
- Price per share
- $5.76
- Number of holders
- 7
- Value change
- +$529,238
- Number of buys
- 3
- Number of sells
- 4
Report period
Q1 2025
Institutions
7
Top holders
7
NEUP full security history
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Neuphoria Therapeutics Inc. SEC filings
Neuphoria Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 64136E102
Recent filing periods:
Top shareholders of NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,033,796
|
$5,365,401 | $0 | 31 Dec 2024 | |
| Apeiron Investment Group Ltd. |
13D/G
|
— |
4.5%
|
72,618
|
$376,887 | $0 | 24 Jan 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
0.85%
|
45,806
|
$157,115 | — | 31 Dec 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.25%
|
13,311
|
$45,657 | — | 31 Dec 2024 | |
| Merck & Co., Inc. |
13F
|
Company |
0.18%
|
10,027
|
$34,393 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.12%
|
6,484
|
$22,240 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
2,978
|
$10,215 | — | 31 Dec 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.02%
|
1,106
|
$3,791 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
7
|
$24 | — | 31 Dec 2024 |
Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) as of Q1 2025
As of 31 Mar 2025,
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) was held by
7 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
163,114 shares.
The largest 7 holders included
AdvisorShares Investments LLC, Lynx1 Capital Management LP, Prosperity Wealth Management, Inc., Merck & Co., Inc., Cyndeo Wealth Partners, LLC, RHUMBLINE ADVISERS, and MORGAN STANLEY.
This page lists
7
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
7
Q1 2025 holders
7
Holder diff
0
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.